
Keywords: ALAS1; 5-aminolevulinate synthase 1; ANT; anthracycline; BVR A; biliverdin reductase A; COX1, COX4; mitochondrial and nuclear genome-encoded complex IV subunits, respectively; DAU; daunorubicin; DEX; dexrazoxane; FU; post-treatment follow up; GSH; reduced